The utility of indirect predictors of hepatitis C viremia

Drug and Alcohol Dependence

Volumn 74, Issue 1, 2004, Pages 15-19

  Sylvestre, Diana L ^a,b   Clements, Barry J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alanine transaminase; Biomarkers; Hepatitis C; Liver function test; Virology

Indexed keywords

BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AFRICAN AMERICAN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; DEMOGRAPHY; DRUG ABUSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VIREMIA;

HEPATITIS C VIRUS;

EID: 1842504492     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2003.11.006     Document Type: Article

References (21)

1. Alter M.J. Hepatitis C virus infection in the United States. J. Hepatol. 31(Suppl. 1):1999;88-91.
2. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N. Engl. J. Med. 327:1992;1899-1905.
3. Alter M.J., Moyer L.A. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(Suppl. 1):1998;S6-S10.
4. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 34:2001;188-193.
5. CDC, 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 47, 1-39.
6. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(Suppl. 1):1998;S11-S19.
7. Garfein R.S., Vlahov D., Galai N., Doherty M.C., Nelson K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health. 86:1996;655-661.
8. Howell C., Jeffers L., Hoofnagle J.H. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology. 119:2000;1385-1396.
9. Inglesby T.V., Rai R., Astemborski J., Gruskin L., Nelson K.E., Vlahov D., Thomas D.L. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 29:1999;590-596.
10. Khan M.H., Farrell G.C., Byth K., Lin R., Weltman M., George J., Samarasinghe D., Kench J., Kaba S., Crewe E., Liddle C. Which patients with hepatitis C develop liver complications? Hepatology. 31:2000;513-520.
11. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345:2001;41-52.
12. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
13. McCarthy J.J., Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J. Addict Dis. 20:2001;19-31.
14. Minuk G.Y. The influence of host factors on the natural history of chronic hepatitis C viral infections. J. Viral Hepat. 6:1999;271-276.
15. National Institutes of Health, 2002. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 10-12 June 2002. Hepatology 36, S3-S20.
16. Nyamathi A.M., Dixon E.L., Robbins W., Smith C., Wiley D., Leake B., Longshore D., Gelberg L. Risk factors for hepatitis C virus infection among homeless adults. J. Gen. Intern. Med. 17:2002;134-143.
17. Page-Shafer K.A., Cahoon-Young B., Klausner J.D., Morrow S., Molitor F., Ruiz J., McFarland W. Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection. Am. J. Public Health. 92:2002;670-676.
18. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34:2001;730-739.
19. Sylvestre D.L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 67:2002;117-123.
20. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., Hashimoto E., Lefkowitch J.H., Ludwig J., Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
21. Zeldis J.B., Jain S., Kuramoto I.K., Richards C., Sazama K., Samuels S., Holland P.V., Flynn N. Seroepidemiology of viral infections among intravenous drug users in northern California. West J. Med. 156:1992;30-35.